Australian regenerative medicine company Orthocell (ASX:OCC) has strengthened its North American commercial footprint, appointing a second Canadian distributor for its flagship nerve repair device Remplir, achieving full national coverage across the country's US$75 million nerve repair market.
Remplir is Orthocell’s flagship regenerative nerve repair device, designed to guide the regeneration of damaged peripheral nerves and restore motor and sensory function. The device has regulatory approval in the US, Australia, New Zealand, Singapore, Thailand, Canada and Hong Kong.
The newly appointed Ontario-based distributor has been granted exclusive rights to distribute Remplir across Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland. The appointment complements Orthocell’s existing partnership in Alberta and British Columbia, providing coast-to-coast access for surgeons and patients.
Orthocell Chief Executive Officer and Managing Director Paul Anderson said the expansion was a key step in the company’s global growth strategy.
“We’re very pleased to expand our Canadian distributor presence beyond Alberta and BC with this new appointment opening up the entire Canadian market,” Mr Anderson said. “Our focus remains on rolling out Remplir in the jurisdictions where we have regulatory approvals. The most efficient pathway to market is through in-country distributors with direct relationships with surgeons and hospitals. Each new appointment brings us closer to generating new revenue streams.”
The announcement follows successful launch activities at the American Society for Surgery of the Hand Annual Meeting in Vancouver in October, with the company expecting its first Canadian sales this quarter.
Orthocell said the newly appointed distributor brings significant experience across the nerve, spine, and orthopaedic implant sectors, supported by a team of 30 sales agents and six product managers. The rollout will be supported by Orthocell’s US-based marketing and medical education teams, leveraging established programs that have underpinned the product’s growing adoption in the United States.
Orthocell received Health Canada approval for Remplir in April 2025, following a fast-tracked review that took less than three months from submission to approval.
Mr Anderson said the Canadian expansion builds on the company’s growing international momentum. “We’re building significant traction globally with our distributor relationships — across 25 US states, Hong Kong, and now full Canadian coverage, alongside long-term partnerships in Australia and Singapore,” he said.
With more than $50 million in cash and no debt, Orthocell said it is well-positioned to drive rapid product adoption and deliver a “step change” in revenue in FY26. The company continues to advance its rollout in the US$1.6 billion US nerve repair market, where its distribution network and hospital engagement activities are accelerating.